Compare Illumina, Inc. (ILMN) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Repligen Corporation Common Stock — how do they compare? Illumina, Inc. trades at $270.48 (market cap $41.04B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Illumina, Inc. is far larger — about 3.6× Repligen Corporation Common Stock's market cap, and Illumina, Inc. is more actively traded (2,120,523 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 84 Days and Repligen Corporation Common Stock for 0 Days on average.
| ILMN | RGEN | |
|---|---|---|
Market Cap | $41.04B | $11.31B |
Volume | 2,120,523 | 1,216,919 |
Sector | Health | Health |
52-Week High | $293.69 | $194.57 |
52-Week Low | $93.00 | $102.87 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $42.39B | $11.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.18, down 1.99% but near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has delivered three consecutive earnings beats. Fundamentals improved significantly with 2025 net income turning positive at $850M after years of losses, while revenue remains stable around $4.3B. Valuation metrics appear elevated with P/E at 50.7 and P/S at 9.31, reflecting premium pricing for growth expectations.
The outlook remains positive with analyst consensus favoring Buy ratings (54%) and S&P 500 inclusion providing institutional support. Key catalysts include AI integration in genomics and expanding drugmaker partnerships. Risks include China market headwinds, cost volatility pressuring margins, and high valuation requiring sustained growth. Cash flow stability improved with $291M net inflow in 2025 after previous volatility.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
